Sign in
Taking peopleNo phase

Repeat MRI and ultrasound scans to track giant cell arteritis after treatment

Looks at how scan findings change over time in people with giant cell arteritis.

Key facts

Who runs it
Fondation Ophtalmologique Adolphe de Rothschild
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis) (EvHortim)
Status
Recruiting
People taking part
50 people, planned
Started
28 Nov 2023
Expected to end
Apr 2027
Type of study
Observational
Treatments tested
  • Injected cerebral MRI angiography and ultrasound of the superior aortic trunks, temporal and axillary arteries
Record updated
4 June 2024

Who can take part

The trial is looking for people aged 50 and over with giant cell arteritis (Horton's disease), diagnosed with MRI and ultrasound. Scans are repeated over time to see how the arteries change during treatment.

Age
50 years and over
Sex
All sexes
Disease stage
Giant cell arteritis according to ACR/EULAR 2022 criteria, diagnosed with MRI and ultrasound
Main reasons for not taking part
  • Cannot have an MRI scan, for example due to an incompatible implanted device or fear of closed spaces (claustrophobia)
  • Allergy to gadobutrol, the MRI contrast dye
  • Under legal protection
  • Pregnant or breast-feeding women
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Patient aged 50 and over
  • Having received informed consent to participate in the study
  • Affiliated or beneficiary of a social insurance scheme
  • Patients with giant cell arteritis according to ACR/EULAR 2022 criteria
  • Diagnosed with MRI and ultrasound

Who cannot take part

  • Hypersensitivity to gadobutrol
  • Absolute or relative contraindication to MRI (incompatible implantable device, claustrophobia, etc.)
  • Patient under legal protection
  • Pregnant or breast-feeding women

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Giant cell arteritis

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Giant cell arteritis (GCA), also known as Horton's disease, is an inflammatory arteritis of the large and medium-sized arteries, with an estimated incidence of 17.8/100,000 in people over 50.

Read full original descriptionShow less

The disease presents potential ophthalmological, neurological, cardiac and aortic vascular complications, making diagnosis an emergency in cases of suspected Horton's disease.

only corticosteroid therapy started as early as possible can prevent these complications.

Diagnosis has historically relied on temporal artery biopsy, but the recent ACR/EULAR 2022 classification criteria propose alternatives to this invasive examination, in particular imaging tests such as temporal artery ultrasound and PET scans. Although not included in these latest recommendations, high-definition wall MRI can also provide arguments in favor of this diagnosis, and avoid the need for a temporal artery biopsy, the sensitivity of which is only 75%. The investigators recently demonstrated in a prospective cohort that wall MRI, possibly coupled with temporal artery ultrasound or retinal angiography, was far superior to temporal artery biopsy in diagnostic performance.

The main limitation of these imaging tests is the lack of data in the literature on the evolution of abnormalities over time, and in particular after initiation of oral corticosteroid therapy. This uncertainty makes it difficult to use these examinations to monitor disease activity, particularly in cases of suspected relapse, a frequent situation in which the clinician is regularly put at fault due to an often frustrating symptomatology and the possible absence of a frank biological inflammatory syndrome.

The investigators propose to conduct a study aimed at describing the evolution of cranial vessel wall abnormalities on wall MRI and ultrasound by systematically repeating these examinations at 1 month, 3 months from the initial MRI performed at diagnosis, in addition to the follow-up performed as part of care at 6 and 12 months from diagnosis. In the event of a relapse in the intervening period, a new MRI scan can be performed and compared with the most recent MRI scan, to look for evidence of disease activity.

Treatments tested

  • Injected cerebral MRI angiography and ultrasound of the superior aortic trunks, temporal and axillary arteries

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis)
Plain-language title
Repeat MRI and ultrasound scans to track giant cell arteritis after treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06004154, who can take part
Record updated
4 June 2024